ニロチニブ
ニロチニブ 物理性質
- 融点 :
- 231-233 °C
- 比重(密度) :
- 1.36
- 貯蔵温度 :
- -20°C Freezer
- 溶解性:
- DMSO に可溶 (50 mg/ml まで)
- 外見 :
- ベージュパウダー。
- 色:
- オフホワイト
- 安定性：:
- -20°C の DMSO 溶液で最大 1 か月間保存できます。
- InChIKey:
- HHZIURLSWUIHRB-UHFFFAOYSA-N
- SMILES:
- N1(C=C(C)N=C1)C1C=C(C=C(C=1)NC(=O)C1C=CC(C)=C(NC2=NC=CC(C3=CC=CN=C3)=N2)C=1)C(F)(F)F
- CAS データベース:
- 641571-10-0(CAS DataBase Reference)
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
SML3799 |
Nilotinib ≥98% (HPLC)
≥98% (HPLC) |
641571-10-0 |
10mg |
￥14100 |
2024-03-01 |
購入 |
|
Sigma-Aldrich Japan
|
Y0002100 |
システム適合性用ニロチニブ European Pharmacopoeia (EP) Reference Standard
European Pharmacopoeia (EP) Reference Standard |
641571-10-0 |
Y0002100 |
￥19100 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
SML3799 |
Nilotinib ≥98% (HPLC)
≥98% (HPLC) |
641571-10-0 |
50mg |
￥56800 |
2024-03-01 |
購入 |
ニロチニブ 化学特性,用途語,生産方法
効能
抗悪性腫瘍薬, チロシンキナーゼ阻害薬
説明
Chronic myeloid leukemia (CML), a hematological stem-cell disorder, is
definitively diagnosed by the detection of the Philadelphia chromosome, a
truncated version of chromosome 22 resulting from the reciprocal translocation
of chromosomes 9 and 22 induced by a single mutagenic event. The consequence is
the juxtaposition of two genes creating a fusion gene BCR-ABL. This gene leads to
the translation of a fusion protein with increased tyrosine kinase activity that
contributes to the pathogenesis of CML. Targeting the BCR-ABL protein has led to
the successful intervention of the disease. Now established as first-line therapy for
CML, imatinib was the first selective tyrosine kinase inhibitor of BCR-ABL. Since
imatinib only binds to an inactive conformation of the ABL kinase portion, the
conformational restrictions contribute to its selectivity.
化学的特性
Off-White Solid
使用
Nilotinib, an orally active signal transduction inhibitor
that selectively inhibits the tyrosine kinase Bcr-Abl, was
discovered and developed by Norvartis and was launched for
the treatment of chronic myeloid leukemia (CML) in patients
with Philadelphia chromosome-positive (Ph+) disease who
are resistant or intolerant to imatinib mesilate. Additional
clinical trials are currently underway for the treatment
of acute lymphoblastic leukemia (ALL) and gastrointestinal
stromal tumors (GISTs).
定義
ChEBI: Nilotinib is a member of (trifluoromethyl)benzenes, a member of pyrimidines, a member of pyridines, a member of imidazoles, a secondary amino compound and a secondary carboxamide. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and an anticoronaviral agent.
ニロチニブ 上流と下流の製品情報
原材料
準備製品
ニロチニブ 生産企業
Global( 455)Suppliers
641571-10-0(ニロチニブ)キーワード:
- 641571-10-0
- Nilotinib
- Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-
- Nilotinib(TINIBS )
- 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide
- 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide
- Nilotinib & its intermediates
- Nilotinib for research
- Nilotinib(AMN 107)
- Nilotinib, AMN107, Tasigna
- TASIGNA NILOTINIB
- AMN107; TASIGNA
- 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimid
- Nilotinib &aMp
- 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide Nilotinib (AMN-107)
- Nilotinib 4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide
- Nilotinib, >=99%
- 4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyri
- CS-307
- TASIGNA;AMN-107;AMN107
- Nilotinib USP/EP/BP
- Nilotinibr
- NilotinibQ: What is
Nilotinib Q: What is the CAS Number of
Nilotinib Q: What is the storage condition of
Nilotinib
- AMN 107
- 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4 -pyridin-3-ylpyrimidin-2-yl)amino]benzamide
- Tasigna
- Nilotinib-d6
- 4-Methyl-N-[3-(4-methyl-1-imidazolyl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]benzamide
- 4-Methyl-N-[3-(4-Methyl-1H-Imidazol-1-yl)-5- (Tri?uoromethyl) Phenyl]-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino] Benzamide
- N - [3- (4-methyl-1-imidazolyl) -5-trifluoromethylphenyl] -3- [[4- (3-pyridyl) -2-pyrimidinyl] amino] -4-methylbenzamide
- ニロチニブ
- N-[3-(トリフルオロメチル)-5-(4-メチル-1H-イミダゾール-1-イル)フェニル]-4-メチル-3-[4-(3-ピリジル)-2-ピリミジニルアミノ]ベンズアミド
- 4-メチル-N-[3-(4-メチル-1H-イミダゾール-1-イル)-5-(トリフルオロメチル)フェニル]-3-{[4-(ピリジン-3-イル)ピリミジン-2-イル]アミノ}ベンズアミド
- 4-メチル-N-[3-(4-メチル-1H-イミダゾール-1-イル)-5-(トリフルオロメチル)フェニル]-3-[[4-(3-ピリジル)-2-ピリミジニル]アミノ]ベンズアミド
- N-[3-(4-メチル-1H-イミダゾール-1-イル)-5-(トリフルオロメチル)フェニル]-4-メチル-3-[4-(3-ピリジル)ピリミジン-2-イルアミノ]ベンズアミド